A new fluorescence immunoassaytechnique, particle concentration fluorescence immunoassay (PCFIA), has been developedfor quantifyingthe human Immunoglobulins(IgA, 1gM, and lgG). In these "two-site sandwich assays," the capture antibody is immobilized on small polystyrene spheres and the tracer is fluorescein-labeled antibody. Polystyrene particles less than 1 pm in diameter make up the solid phase, to which goat anti-human antibody for each respective assay is attached. Serum specimens are diluted assay. These techniques provide adequate results, but less-expensive methods are needed to rapidly quantify and characterize protein abnormalities, in particular the Ig disorders (1). A new fluorescence immunoassay technique, particle concentration fluorescence immunoassay (PCFIA) (2), offers the specificity of immunoassay and rapid batch quantification of human IgA, 1gM, and IgG.' In PCFIA, immunoreactive species are bound to small particles, typically 0.8-pm-diameter polystyrene; the resulting solid phase is dispersed in the sample, and labeled reagent is added. After analyte and labeled reagent bind on the surface of the particles, the reaction mixture is filtered, washed, and the total particle-bound fluorescence determined. By using a reaction well with a 2-mm-diameter ifitration area ( and careful selection of materials to be used in, e.g., the filter membrane, the assay plate, and the solid phase.
free label by filtration,washes the solid phase, and determines the total particle-boundfluorescenceby front-surface fluonmetry or epifluorescence,calculatesresults,and generates detailedreports.Ninety-sixspecimensmay be analyzed in 29 mm or 960 specimensin 136 assay. These techniques provide adequate results, but less-expensive methods are needed to rapidly quantify and characterize protein abnormalities, in particular the Ig disorders (1). A new fluorescence immunoassay technique, particle concentration fluorescence immunoassay (PCFIA) (2) , offers the specificity of immunoassay and rapid batch quantification of human IgA, 1gM, and IgG.' In PCFIA, immunoreactive species are bound to small particles, typically 0.8-pm-diameter polystyrene; the resulting solid phase is dispersed in the sample, and labeled reagent is added. After analyte and labeled reagent bind on the surface of the particles, the reaction mixture is filtered, washed, and the total particle-bound fluorescence determined. By using a reaction well with a 2-mm-diameter ifitration area (Figure   1 and careful selection of materials to be used in, e.g., the filter membrane, the assay plate, and the solid phase. Polyclonal antibody was passively adsorbed to the polystyrene latex particles at an antibody concentration of 100 pglmL and a particle concentration of 5 mg/mL in 20 mL of 0.1 mol/L sodium acetate buffer, pH 4.0. After letting the reaction mixture stand for 2 h, with periodic vortex-mixing, we centrifuged the particles at approximately 3000 x g for 15 mm, then decanted the supernate. We resuspended the particles in 40 mL of isotonic buffered saline (IBS) (Ameri- Compounds used to test cross-reactivity were obtained commercially (purified IgA and 1gM from Pel Freeze Biologicals, Rogers, AR 72756, and purified IgG from Cappel, Division of CooperBiomedical).
Materials and Methods

Materials
Special Apparatus
A special microprocessor-eontrolled fluorimeter designed to measure epifluorescence was constructed in our laboratories (Screen Machin&", Pandex Laboratories). [In epifluorescence the emitted light passes through the same optical path as the excited light.] The samplesare diluted with the 
Procedures
The IgA and 1gM assaysare performedas follows:Using the Digiflex pipettor, we make two serial dilutions of sample. First, 74 of sample is aspiratedand dispensedinto 
Results
Standard Curves
Figure 2 illustrates typical standard curves for IgA, 1gM, and IgG by PCFIA. The IgA standard curve exhibits a "hook" or prozone effect (the ratio of the intensity decreases) at a concentration greater than 1200 mg/dL. The 1gM standard curve exhibits a hook effect at concentrations greater than 1400 mg/dL, the IgG standard curve at concentration greater than 4500 mgldL.
The antibody-coated particles are stable for one week at both 37#{176}C and45#{176}C, and are also stabletoafreeze-thaw cycle. Given our previous experience with reagent stability at warmer temperatures, the solidphase should be stable for at least two years at 2-8 #{176}C. The current FFFC tracers, however, will not be similarly stable 2-8 #{176}C in the diluted format, and we suggest that they be freshly diluted before use.
Incubations times may be minimized by increasing the concentrations of tracer and analyte in the reaction mixture.
In the IgA assay, changing the sample dilution from 5000-to 2000-fold and increasing the tracer concentrationfrom 5 to 30 zg/mL yielded identical standard curves for incubation periods of 7, 10, or 30 miii.
Analytical Variables
Specificity. The affinity-purified antibodies were monospecific as determined by various methods. All of the antibodies were tested with purified immunoglobulins by PCFIA. Sensitivity. Sensitivity, the lowest concentration that can be detected with 95% confidence, was determined by assaying five replicates of the zero standard. We calculated the sensitivity asthat concentrationdetectable at 2 SD from the mean for the zero standard. Our results for this analytical system were as follows: 14 mg/dL for IgA, 10 mgldL for 1gM, and 11 mg/dL for IgG.
Antibody to
Precision.
We determined within-assay-plate reproducibility by running eight replicates of low, medium, and high controls for each immunoglobulin ( Table 1 ). The withinplate CVs were <10% for all the assays. We currently (April
1985)
recommend including a standard curve on every assay plate with the unknown samples.
Also, the PCFIA system includes a fluorescent internal standard in the antibody-coated particle solution, which compensates for errors in pipetting particles, differences in assay plates, differences between well positions, and varia- rene particles allow for faster reaction rates than do other technologies: their high surface-area-to-volume ratio and their natural brownian motion keep the reagents and analytes continuously mixing and suspended in solution for an extended period. The large dilutions of patient's serum (5000-and 20000-fold) required for these assays demonstrate the high sensitivity of the system, especially for high-molecular-mass analytes, which, until now, have been the domain of enzyme immunoassay or solid-phase RIA. We believethat any possible interferences in the immunoglobulin assayswill be negligible at the large dilutions used. In another assay system under development in our laboratories (unpublished data), in which 20 L of a 50-fold dilution of specimen is used,we saw no problems with icteric, hemolytic, or lipemic specimens. The good precision, recovery, and correlation with an existing method for quantifying immunoglobulins demonstrate the accuracy and clinical utility of PCFIA.
